An early trial of daraxonrasib combined with chemotherapy has reported tumour responses in people with pancreatic cancer that had spread elsewhere in the body. Findings released on 20 November for the EORTC-NCI-AACR symposium in Barcelona concern a first-line treatment combination. Conference release.
The phase I/II RMC-GI-102 study involved 61 patients who had not previously received treatment for metastatic disease. They received the daily pill alongside gemcitabine and nab-paclitaxel chemotherapy. At the September data cut-off, median follow-up was 18.3 months. Study details.
Tumours shrank or became undetectable in 60.7% of patients, including complete responses in 8.2%. Disease control, covering responding or stable cancer, was recorded in 90.2%. The study was sponsored by Revolution Medicines. Results and sponsorship.
Reported side effects included rash, diarrhoea and fatigue. Treatment was discontinued because of daraxonrasib-related side effects in 5% of patients. Safety findings.
What the findings can show
Cancer Research UK’s Dr Sam Godfrey welcomed the findings but told the BBC that longer trials and follow-up were vital. Cancer can return even when scans show no detectable disease, so a response does not establish that a patient is cancer-free. BBC reporting.
Professor Shivan Sivakumar, professor of translational oncology at the University of Birmingham, described the results as encouraging while stressing the limits of a small study without a randomised control group. Comparing its results with historical chemotherapy figures cannot definitively show that the new combination is better. Whether it prolongs overall survival remains unknown. University of Birmingham expert assessment.
Sivakumar said the international phase III RASolute 303 trial would be critical to establishing whether the combination improves survival compared with standard chemotherapy. That question remains separate from whether tumours initially respond to treatment. Next research step.
A different treatment setting
Daraxonrasib already has a US approval, granted by the Food and Drug Administration on 26 August 2026. It covers adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy, or who are not candidates for multiagent systemic therapy. That earlier regulatory decision is distinct from the new first-line combination findings. FDA indication and date.
Cover: AI-generated illustration of a microscope, notebook and glass sample vials on an imagined laboratory bench.
Comments are disabled.












